CliniMACS Prodigy® Instrument

Selected references 

Download the overview of CliniMACS Prodigy® - selected references

1. Lock, D. et al. (2017) Automated manufacturing of potent CD20-directed chimeric antigen receptor T cells for clinical use. Hum. Gene Ther. 28(10): 914-925
2. Klöß, S et al. (2017) Optimization of human NK cell manufacturing: Fully automated separation, improved ex vivo expansion using IL-21 with autologous feeder cells, and generation of Anti-CD123-CAR-expressing effector cells. Hum. Gene Ther. 28(10): 897-913
3. Editorial (2017) The key to unlocking CARs. Nat. Biotechnol. 35(10): 889
4. Tarnowski, J. et al. (2017) Delivering advanced therapies: the big pharma approach. Gene Ther. 24(9): 593-598
5. Fraser, A. R. et al. (2017) Development, functional characterization and validation of methodology for GMP-compliant manufacture of phagocytic macrophages: A novel cellular therapeutic for liver cirrhosis. Cytotherapy 19(9): 1113-1124
6. Pello, O. M. et al. (2017) BKV-specific T cells in the treatment of severe refractory haemorrhagic cystitis after HLA-haploidentical haematopoietic cell transplantation. Eur. J. Haematol. 98(6): 632-634
7. Skorska, A. et al. (2017) GMP-conformant on-site manufacturing of a CD133(+) stem cell product for cardiovascular regeneration. Stem Cell Res. Ther. 8(1): 33
8. Levine, B. L. et al. (2016) Global manufacturing of CAR T cell therapy. Mol. Ther. Methods Clin. Dev. 4: 92-101
9. Priesner, C. et al. (2016) Automated enrichment, transduction and expansion of clinical-scale CD62L+ T cells for manufacturing of GTMPs. Hum. Gene Ther. 27(10): 860-869
10. Priesner, C. et al. (2016) Comparative analysis of clinical-scale IFN-γ-positive T cell enrichment using partially and fully integrated platforms. Front Immunol 7: 393
11. Mock, U. et al. (2016) Automated manufacturing of chimeric antigen receptor T cells for adoptive immunotherapy using CliniMACS prodigy. Cytotherapy 18(8): 1002-1011
12. Takashi, I. et al. (2016) Multiple allogeneic progenitors in combination function as a unit to support early transient hematopoiesis in transplantation. J. Exp. Med. 213(9): 1865-1880
13. Wang, X. and Rivière, I. (2016) Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol. Ther. Oncolytics 3: 16015
14. Walker, A. and Johnson, R. (2016) Commercialization of cellular immunotherapies for cancer. Biochem. Soc. Trans. 44(2): 329-332
15. Hümmer, C. et al. (2016) Automation of cellular therapy product manufacturing: results of a split validation comparing CD34 selection of peripheral blood stem cell apheresis product with a semi-manual vs. an automatic procedure. J. Transl. Med. 14: 76
16. Stroncek, D. F. et al. (2016) Preliminary evaluation of a highly automated instrument for the selection of CD34+ cells from mobilized peripheral blood stem cell concentrates. Transfusion 56(2): 511-517
17. Bunos, M. et al. (2015) Automated isolation of primary antigen-specific T cells from donor lymphocyte concentrates: results of a feasibility exercise. Vox sang. 109(4): 387-393
18. Spohn, G. et al. (2015) Automated CD34+ cell isolation of peripheral blood stem cell apheresis product. Cytotherapy 17(10): 1465-1471
19. Kumaresan, P. et al. (2015) Automated cell enrichment of cytomegalovirus-specific T cells for clinical applications using the cytokine-capture system. J. Vis. Exp. 104: e52808
20. Sorg, N. et al. (2015) Red blood cell depletion from bone marrow and peripheral blood buffy coat: a comparison of two new and three established technologies. Transfusion 55(6): 1275-1282
21. Granzin, M. et al. (2015) Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy. Cytotherapy 17(5): 631-632
22. Apel, M. et al. (2013) Integrated clinical scale manufacturing system for cellular products derived by magnetic cell separation, centrifugation and cell culture. Chemie Ingenieur Technik 85: 103-110

Brochures and posters 

• CliniMACS Prodigy Platform 
• CliniMACS Prodigy T Cell Transduction 
• CliniMACS Prodigy ACC Application Sheet pluripotent stem cell expansion 
• CAR T cells 
• CliniMACS Prodigy ACC Application Sheet - mesenchymal stem cell expansion 
• CliniMACS Prodigy ACC Application Sheet - PSC to mesencephalic dopaminergic progenitor differentiation 
• CliniMACS Prodigy TCT Transduction Application Sheet
• CliniMACS Prodigy HSC Engineering Application Sheet

Scientific posters 

• Automation of hematopoietic stem cell transduction: Results of a head-to-head comparison between a manual and an automated procedure. Bissels, U. et al. (2019) ESGCT
• Efficient GMP-compliant expansion of mesenchymal stromalcells (MSCs) from umbilical cord, bone marrow, and adiposetissue using a closed cultivation system. Godthardt, K. - ISCT 2019
• GMP-compliant expansion of mesenchymal stromal cells (MSCs) using the CliniMACS Prodigy® and xeno-free MSC-Brew GMP Medium
• Fully integrated closed-system expansion and differentiation of pluripotent stem cells towards mesencephalic dopaminergic progenitor cells. 
• Scalable process for standardized generation of human PSC-derived cardiomyocytes. 
• Standardized QC assays and (automated) expansion of pluripotent stem cells 
• Safety assessment of MACS® GMP T Cell TransAct 
• Automated manufacturing of gene-engineered T cells under serum-free conditions 
• Automated clinical-scale retroviral transduction of T cells in a functionally closed system 
• Polyclonal T cell activation and expansion tool for clinical-scale manufacturing - ICIC 2017 
• Effective retroviral transduction of primary T cells and hematopoieticstem cells using the soluble transduction enhancer: Vectofusin-1®

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. For complete regulatory notes, please click here.